SEC Form 4 · accession 0001662521-26-000002
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernadette Connaughton
Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 11, 2026 · 5:43 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | S | 1,626 | $102.80 | D | 40,418 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.